Short answer
Dexcom (DXCM) filed an 8-K current report with the SEC on March 2, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Sayer returns from leave March 2, 2026, resuming Executive Chairman role; Mark Foletta steps back from interim Lead Independent Director duties.
Dexcom 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Sayer returns from leave March 2, 2026, resuming Executive Chairman role; Mark Foletta steps back from interim Lead Independent Director duties
- New comp package: $610,000 annual base salary as Executive Chairman
- RSU grant of $2,350,000 fair value, cliff-vesting March 8, 2027, contingent on continued service
- Prior equity awards continue vesting on original schedules: no accelerated vesting or clawback triggered by leave
- Sayer excluded from Severance & Change in Control Plan, reducing company's financial exposure if he departs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dexcom 8-K filings
Get the next DXCM 8-K as it lands
Follow DXCM for push alerts, or ask the research agent what this filing means.